UFF
XENT

USA Financial Formulas’s Intersect ENT, Inc XENT Stock Holding History

USA Financial Formulas’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,538
Closed -$484K – 359
2017
Q3 		$484K Buy
+15,538
New +$460K 0.12% 176

Other funds holding XENT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

USA Financial Formulas's XENT Position: Q4 2017 in Review

USA Financial Formulas sold out of Intersect ENT, Inc (XENT) in Q4 2017, closing a stake of 15,538 shares — an estimated $484K sold.

USA Financial Formulas first reported a position in XENT in Q3 2017 and held it in 1 quarter. The position peaked at $484K in Q3 2017. 157 funds tracked by Wall St. Rank hold XENT as of Q4 2017.

  • USA Financial Formulas reported no remaining Intersect ENT, Inc position as of Q4 2017 after selling out during the quarter.
  • USA Financial Formulas sold 15,538 Intersect ENT, Inc shares in Q4 2017, an estimated $484K.
  • USA Financial Formulas first reported a position in Intersect ENT, Inc in Q3 2017 and held it in 1 quarter.
  • USA Financial Formulas's Intersect ENT, Inc position peaked at $484K in Q3 2017.
  • 157 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q4 2017.

Based on USA Financial Formulas's 13F filing for Q4 2017, filed 13 Feb 2018.